超进展-免疫治疗相关现象与癌症的内在自然史——回应 - Suppr

Suppr

超能文献

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.

作者信息

Ferrara Roberto, Caramella Caroline, Besse Benjamin

机构信息

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Deparment of Radiology, Gustave Roussy, Villejuif, France.

出版信息

JAMA Oncol. 2019 May 1;5(5):744. doi: 10.1001/jamaoncol.2019.0138.

DOI:10.1001/jamaoncol.2019.0138

PMID:30896761

Abstract

摘要

相似文献

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.

JAMA Oncol. 2019 May 1;5(5):744. doi: 10.1001/jamaoncol.2019.0138.

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.

JAMA Oncol. 2019 May 1;5(5):743. doi: 10.1001/jamaoncol.2019.0130.

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.

Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.

Hyperprogression during immunotherapy: do we really want to know?

Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184.

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Thorac Cancer. 2019 Feb;10(2):401. doi: 10.1111/1759-7714.12926. Epub 2018 Dec 8.

[Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].

Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):585-589. doi: 10.3760/cma.j.issn.0529-5807.2019.08.001.

There and back again: An immunotherapy tale.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

KEYNOTE-024: Unlocking a pathway to lung cancer cure?

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.

Programmed death of chemotherapy in non-small-cell lung cancer?

Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.

引用本文的文献

Gut Microbiota and Breast Cancer: The Dual Role of Microbes.

Cancers (Basel). 2023 Jan 10;15(2):443. doi: 10.3390/cancers15020443.

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001882.

Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.

Curr Oncol Rep. 2020 Apr 16;22(5):41. doi: 10.1007/s11912-020-00908-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.

JAMA Oncol. 2019 May 1;5(5):744. doi: 10.1001/jamaoncol.2019.0138.

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.

JAMA Oncol. 2019 May 1;5(5):743. doi: 10.1001/jamaoncol.2019.0130.

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.

Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.

Hyperprogression during immunotherapy: do we really want to know?

Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184.

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Thorac Cancer. 2019 Feb;10(2):401. doi: 10.1111/1759-7714.12926. Epub 2018 Dec 8.

[Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].

Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):585-589. doi: 10.3760/cma.j.issn.0529-5807.2019.08.001.

There and back again: An immunotherapy tale.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.

Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.

Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

KEYNOTE-024: Unlocking a pathway to lung cancer cure?

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.

Programmed death of chemotherapy in non-small-cell lung cancer?

Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.

引用本文的文献

Gut Microbiota and Breast Cancer: The Dual Role of Microbes.

Cancers (Basel). 2023 Jan 10;15(2):443. doi: 10.3390/cancers15020443.

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001882.

Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.

Curr Oncol Rep. 2020 Apr 16;22(5):41. doi: 10.1007/s11912-020-00908-9.